Stock Scorecard



Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $284.47 as of 9/14/2026 11:25:58 AM EST

Total Score

13 out of 30

Safety Score

60 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LGND

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LGND

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LGND

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LGND

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LGND (60 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LGND

Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock 8/19/2026 7:43:00 AM
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run 8/14/2026 3:28:00 AM
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals 8/13/2026 6:39:00 PM
Ligand Pharmaceuticals Q2 Earnings Call Highlights 8/6/2026 9:09:00 PM
Janus Henderson Group PLC Raises Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND 7/30/2026 5:41:00 PM
LGND|Ligand Pharmaceuticals Inc|Price:289.855|Chg%:+2.315 7/30/2026 5:41:00 PM
July 2026's Stocks That May Be Priced Below Estimated Value 7/24/2026 2:44:00 AM
Bessemer Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated $LGND 7/22/2026 2:12:00 PM
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks 7/22/2026 11:11:00 AM
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TMHC, CZR, XOMA, and RAMP 6/28/2026 12:11:00 PM

Financial Details for LGND

Company Overview

Ticker LGND
Company Name Ligand Pharmaceuticals Inc - Class B
Country USA
Description Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 284.47
Price 4 Years Ago 66.80
Last Day Price Updated 9/14/2026 11:25:58 AM EST
Last Day Volume 261,166
Average Daily Volume 222,650
52-Week High 326.63
52-Week Low 161.82
Last Price to 52 Week Low 75.79%

Valuation Measures

Trailing PE 29.70
Industry PE 23.62
Sector PE 57.82
5-Year Average PE 31.09
Free Cash Flow Ratio 5.63
Industry Free Cash Flow Ratio 10.83
Sector Free Cash Flow Ratio 25.47
Current Ratio Most Recent Quarter 31.18
Total Cash Per Share 50.50
Book Value Per Share Most Recent Quarter 48.57
Price to Book Ratio 5.94
Industry Price to Book Ratio 3.27
Sector Price to Book Ratio 10.35
Price to Sales Ratio Twelve Trailing Months 19.85
Industry Price to Sales Ratio Twelve Trailing Months 38.16
Sector Price to Sales Ratio Twelve Trailing Months 14.18
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 19,935,600
Market Capitalization 5,671,080,132
Institutional Ownership 116.00%

Dividends

Ex-Dividend Date 7/2/2010
Previous Dividend Amount 0.0000
Current Dividend Amount 0.4560
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage -96.96%
3-Year Dividend Growth Rate Percentage -96.96%
5-Year Dividend Growth Rate Percentage -96.96%
All-Time Dividend Growth Rate Percentage -96.96%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 825.00%
Annual Earnings Growth 3,186.63%
Reported EPS 12 Trailing Months 9.74
Reported EPS Past Year 3.85
Reported EPS Prior Year 6.78
Net Income Twelve Trailing Months 197,220,000
Net Income Past Year 124,453,000
Net Income Prior Year -4,032,000
Quarterly Revenue Growth YOY 33.70%
5-Year Revenue Growth 10.39%
Operating Margin Twelve Trailing Months 13.50%

Balance Sheet

Total Cash Most Recent Quarter 1,006,702,000
Total Cash Past Year 174,927,000
Total Cash Prior Year 72,307,000
Net Cash Position Most Recent Quarter -119,892,000
Net Cash Position Past Year -271,265,000
Long Term Debt Past Year 446,192,000
Long Term Debt Prior Year 76,695,000
Total Debt Most Recent Quarter 1,126,594,000
Equity to Debt Ratio Past Year 0.70
Equity to Debt Ratio Most Recent Quarter 0.46
Total Stockholder Equity Past Year 1,017,212,000
Total Stockholder Equity Prior Year 830,439,000
Total Stockholder Equity Most Recent Quarter 967,516,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 131,365,000
Free Cash Flow Per Share Twelve Trailing Months 6.59
Free Cash Flow Past Year 48,907,000
Free Cash Flow Prior Year 77,407,000

Options

Put/Call Ratio 0.33
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 206.37
20-Day Bollinger Middle Band 272.55
20-Day Bollinger Upper Band 338.73
Beta 0.98
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 9/12/2026 2:25:29 AM EST